IDDF2019-ABS-0270 ECT2 Increases egfr expression and tumorigenicity by promoting Cdc42 activity in pancreatic cancer

Junxiong Wang
2019 Basic gastroenterology   unpublished
binding to proteins and regulating cellular metabolism. The aim of this study was to identify a certain lncRNA promoting the progress of advanced colorectal cancer (CRC) with a therapeutic perspective. Methods We screened out highly expressed lncRNAs using samples from patients with stage IV CRC compared with matched adjacent normal tissues. The proteins interacted with linc00920 was confirmed with RNA pull-down and RNA immunoprecipitation (RIP) assay. The proliferation and metabolic alteration
more » ... etabolic alteration of CRC under linc00920 inhibition were tested in vitro and in vivo. Results Linc00920 was upregulated in CRC with poor overall survival and inhibition of linc00920 resulted in impaired growth of CRC cell lines. Moreover, knocking down of linc00920 was consistent with a lower level of insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2), which is known as a m 6 A 'reader' and mRNA stabilizer. Linc00920 bound to the ubiquitination sites of IGF2BP2 and prevented its autophagic degradation, maintaining the MYC-mediated glycolysis in CRC. Moreover, inhibition of linc00920 suppressed the proliferation of tumors from patient-derived xenograft (PDX) models. Conclusions Linc00920-IGF2BP2-MYC axis promotes the progress of CRC as a promising therapeutic target.
doi:10.1136/gutjnl-2019-iddfabstracts.54 fatcat:kslhr3kx5fdvjcu2pvjmsunpw4